Sage Therapeutics, Inc. (SAGE) Bought by Supernus to Boost Neuropsychiatric Portfolio
Sage Therapeutics, Inc. (NASDAQ:SAGE) known for its FDA-approved postpartum depression drug Zurzuvae, is acquired by Supernus Pharmaceuticals in a deal valued at up to $795 million.